In a world obsessed with coding the mind through AI, Ampa Health is over here doing something bolder; they’re decoding it directly. The Palo Alto-based neurotech startup just locked an oversubscribed $8.5M Pre-A round led by Nexus NeuroTech Ventures, with Satori Capital, Morningside Ventures, Continuum Health Ventures, and the Zabara Foundation joining the mix. This isn’t just funding; it’s fuel for a company turning brain science into real-world healing.
Co-founders Dr. Don Vaughn, Ph.D., and Dr. Jonathan Downar, M.D., Ph.D. are the kind of duo that makes you believe science can have swagger. Dr. Vaughn, Stanford Physics & Econ, UCLA Neuroscience, has been preaching the gospel of neurohacking long before it was trending. His TEDx talk broke 1M views because he made the brain feel less like a mystery and more like an upgradeable system. Dr. Downar, the Toronto psychiatrist-scientist with 180+ peer-reviewed papers, helped prove depression treatment doesn’t need 36 days when 1 can work just as well. Together, they built Ampa like engineers building a race car: light, fast & built to change the game.
Their creation, the FDA-cleared Ampa One System, is a portable transcranial magnetic stimulation (TMS) device treating depression, anxiety, and addiction with precision once reserved for hospital labs. Two FDA clearances (K243319 & K251210) confirm it matches predicate systems like MagVita B70 and BrainsWay H7, only this one fits into a clinic setup without the overhead nightmare. It’s neurotech scaled like software: lighter, cheaper, faster, smarter.
Then there’s the ONE-D Protocol, the brain’s equivalent of a sprint triathlon. 20 iTBS sessions, spaced every 30 min, all packed into a 9.5-hr treatment day. Patients pre-treated with D-cycloserine and lisdexamphetamine to “fertilize” neuroplasticity. The outcome? 70% remission, 90% response, durable at 6-mo follow-ups. Traditional TMS hits ~50% remission after 36 days. Ampa does it in 1. That’s not marketing; it’s clinical data dressed in hustle.
Nexus NeuroTech Ventures Principal John Propst, Ph.D., MBA, called it straight: Ampa is where scientific innovation meets scalability. That matters because molecules get pricier every year, but tech follows Moore’s Law; the more you build, the cheaper it gets. That’s how mental health treatment stops being elite care and starts being human care.
Ampa’s mission? “1B remissions.” Wild number, sure, but every revolution starts with a single pulse. With Dr. Vaughn leading commercialization and Dr. Downar refining the science, they’re proving mental health doesn’t need to crawl toward progress. It can sprint.
